Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019:2019:10.31487/j.cdm.2019.01.01.
doi: 10.31487/j.cdm.2019.01.01. Epub 2019 Dec 31.

Adenosine vs Regadenoson Pharmacologic Stress Differs in Women with Suspected Coronary Microvascular Dysfunction: A Report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) Study

Affiliations

Adenosine vs Regadenoson Pharmacologic Stress Differs in Women with Suspected Coronary Microvascular Dysfunction: A Report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) Study

Janet Wei et al. Cardiovasc Disord Med. 2019.

Abstract

Background: Stress cardiac magnetic resonance (CMR) imaging with myocardial perfusion reserve index (MPRI) measurement has emerged as a noninvasive method for assessing coronary microvascular dysfunction (CMD) in the absence of obstructive coronary artery disease (CAD). Pharmacologic stress with adenosine or regadenoson is typically used with comparable coronary vasodilation, but higher unadjusted MPRI has been reported with regadenoson in healthy men. This difference has not been assessed in symptomatic or healthy women.

Methods: In a prospective cohort study, 139 symptomatic women with suspected CMD and no obstructive CAD underwent stress CMR and invasive coronary flow reserve (CFR) testing. Adenosine was the default vasodilator (n=99), while regadenoson was used if history of asthma or prior adenosine intolerance (n=40). Stress CMR was also performed in 40 age-matched healthy controls using adenosine (n=20) and regadenoson (n=20). Unpaired t-tests and analysis of covariance were performed to compare MPRI with adenosine and regadenoson in the symptomatic women and healthy controls.

Results: Compared to regadenoson cases, adenosine cases had lower invasive CFR (2.64±0.62 vs 2.94±0.68, p=0.01) and pharmacologic heart rate change (28±16 vs 38±15 bpm, p=0.0008). Unadjusted MPRI was lower in the adenosine compared to regadenoson cases (1.73±0.38 vs 2.27±0.59, p<0.0001). When adjusted for heart rate, rate-pressure-product, and invasive CFR, MPRI remained lower in the adenosine cases (p<0.0001). Invasive CFR to adenosine correlated with adenosine MPRI (r 0.17, p=0.02) but not regadenoson MPRI (r -0.14, p=0.19). There was no significant difference in MPRI in the controls who received adenosine vs regadenoson (2.27±0.33 vs 2.38±0.44, p=0.36).

Conclusion: In women undergoing stress CMR for suspected CMD, those who received adenosine had lower MPRI than those who received regadenoson. However, there were no differences in MPRI in the healthy controls. These findings suggest there may be physiologic differences in adenosine and regadenoson response in the coronary microcirculation of symptomatic women.

Keywords: coronary microvascular dysfunction; myocardial perfusion imaging; women.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Puja K. Mehta has received research grants from Gilead and General Electric. Chrisandra Shufelt has received a research grant from Gilead. Daniel S. Berman has received research grants from Astellas Pharma US, Inc, Bayer Healthcare Pharmaceuticals, and Siemens Medical Solutions. C. Noel Bairey Merz would like to report funding from iRhythm, Abbott Diagnostics, and Sanofi.

Figures

Figure 1:
Figure 1:
Relationship between MPRI (stratified by adenosine or regadenoson stress) and invasive CFR to intracoronary adenosine. MPRI with adenosine mildly correlated with invasive coronary flow reserve to intracoronary adenosine (r 0.17, p=0.02), but MPRI with regadenoson did not correlate with invasive CFR to intracoronary adenosine (r −0.14, p=0.19).

References

    1. Shufelt CL, Thomson LE, Goykhman P, Agarwal M, Mehta PK et al. (2013) Cardiac magnetic resonance imaging myocardial perfusion reserve index assessment in women with microvascular coronary dysfunction and reference controls. Cardiovasc Diagn Ther 3: 153–160. [Crossref] - PMC - PubMed
    1. Thomson LE, Wei J, Agarwal M, Haft Baradaran A, Shufelt C et al. (2015) Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women’s Ischemia Syndrome Evaluation. Circ Cardiovasc Imaging 8. [Crossref] - PMC - PubMed
    1. Doyle M, Weinberg N, Pohost GM, Bairey Merz CN, Shaw LJ et al. (2010) Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Imaging 3: 1030–1036. [Crossref] - PMC - PubMed
    1. Goykhman P, Mehta PK, Agarwal M, Shufelt C, Slomka PJ et al. (2012) Reproducibility of myocardial perfusion reserve - variations in measurements from post processing using commercially available software. Cardiovasc Diagn Ther 2: 268–277. [Crossref] - PMC - PubMed
    1. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD et al. (2007) Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 14: 645–658. [Crossref] - PubMed

LinkOut - more resources